SRRK
HealthcareScholar Rock Holding Corporation
$42.76
$-0.04 (-0.09%)
Jan 5, 2026
Price History (1Y)
Analysis
Scholar Rock Holding Corporation is a healthcare-focused biotechnology company with a market capitalization of $4.36 billion and 128 employees. The company operates in the sector of Healthcare, specifically within the Biotechnology industry. The financial health of Scholar Rock Holding Corporation reveals significant challenges. The company has reported zero profitability, reflected in gross margin, operating margin, and profit margin all at 0.0%. Moreover, its returns on equity (ROE) and return on assets (ROA) are negative, at -218.0% and -76.6%, respectively. The balance sheet shows a debt-to-equity ratio of 44.93 and a cash position of $369.63 million against $110.08 million in debt. The valuation context for Scholar Rock Holding Corporation is characterized by a forward P/E ratio of -14.22, indicating a significant discrepancy between the company's stock price and its earnings potential. The EV/EBITDA ratio also reflects this disparity at -11.38. The lack of dividend information and absence of revenue or net income data further underscores the complexity of evaluating the company's valuation.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Scholar Rock Holding Corporation
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $4.36B
- P/E Ratio
- N/A
- 52-Week High
- $48.28
- 52-Week Low
- $22.71
- Avg Volume
- 2.14M
- Beta
- 0.64
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 128